Genomics, a science-led tech-bio company using large-scale genetic information to develop innovative precision healthcare tools and to accelerate drug discovery and development, has officially announced the launch of Mystra, which happens to be the world’s first ever original AI-enabled human genetics platform focused on supercharging drug target discovery and validation.
To understand the significance of such a development, we must take into account how pharmaceutical industry is currently up against a significant research and development (R&D) productivity crisis. This crisis relates to how the failure rate for drug candidates in clinical trials now stands at a staggering 95%. The stated rate, on its part, has pushed the average cost of bringing a new medicine to market past $2.3 billion.
Against that, Genomics brings forth an industry-leading solution built on the fact that targets with human genetic support are 2.6 times more likely to succeed in clinical trials.
More on the same would reveal how the company reached upon its latest brainchild after ingesting, harmonizing, and quality-controlling what is the world’s largest and most diverse human genotype-phenotype database. In that respect, Genomics’ latest brainchild also provides extensive, powerful insights into human biology, with relevant information for drug development and critical insights into disease mechanisms supported by evidence from studies of genetic variation.
Complementing that would be the availability of proprietary AI and advanced algorithms, each one enabling Genomics’ Foundational Data Collection to cover more than 20,000 genome-wide associated studies (GWAS) and trillions of rows of data.
Talk about the whole value proposition on a slightly deeper level, we begin from Mystra’s promise to provide users with critical insights into disease mechanisms. The solution further brings forth rapid, deep analysis necessary for drug development.
To expand upon that, Mystra turns human genetics from a slow, fragmented, specialist-driven process into a high-speed, integrated capability which then goes on to inform drug discovery and development at scale. This involves unifying genomic data, analysis tools, and collaboration capabilities in one platform.
Not just that, it also facilitates earlier, stronger decision-making in target identification, validation, and clinical trial design, while simultaneously bestowing cross-functional teams with a shared source of truth for genetic evidence.
Another detail worth a mention is rooted in the prospect of building genetic conviction, something which talks to how users can instantly assess the efficacy and safety of drug candidates against the world’s most comprehensive human genetic evidence.
Beyond that, you can also scale up the probability of success for every drug candidate through more strategic selection of drug candidates to achieve higher-quality assets entering the pipeline. Genomics’ own use of the platform is, in fact, poised to contribute dozens of targets towards pharma R&D pipelines
The platform in question markedly works on a self-service model, meaning one can enroll teams for direct access to Mystra. Once enrolled, users can seamlessly get down to leveraging the platform’s proprietary datasets and analysis tools.
Hold on, we still have a couple of bits left to unpack, considering we haven’t yet touched upon how users can also bank upon proprietary internal data to securely combine it with Genomics’ world-leading datasets for bespoke analysis.
Rounding up highlights would be a facility to collaborate with Genomics’ team of over 60 statistical genetic scientists.
“For over a decade, we have been meticulously building and using an unparalleled platform of genetic insights to accelerate our own collaborations with biopharma partners,” said Dave Thornton, President at Genomics. “Today, we are making this breakthrough technology available to the statistical geneticists throughout the R&D community. Mystra transforms fragmented data into actionable, high-conviction insights, empowering statistical geneticists and life sciences companies to make real-time decisions that were previously impossible. We are changing the trajectory of drug development – to bring tomorrow’s medicine for the patients of today, safer and faster.”
